摘要
目的:探讨树突状细胞(dendritic cell,DC)共培养细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)联合化疗治疗晚期胃癌患者的近期疗效。方法:选取28例确诊为晚期胃癌并采用DC-CIK联合化疗的患者为联合治疗组,选取临床资料相近的同期进行单纯化疗的28例晚期胃癌患者为对照组,观察两组患者治疗前后外周血中T细胞亚群、细胞因子及卡氏评分(Karnofsky,KPS)的变化及临床疗效,并记录其不良反应。结果:联合治疗组患者治疗后CD3+、CD4+、CD56+和CD4+/CD8+的比例无明显变化(P>0.05),对照组CD3+、CD4+和CD4+/CD8+的比例治疗后明显下降(P<0.05);联合治疗组的细胞因子IL-12和IFN-γ的水平治疗后有所上升(P<0.05),治疗组IL-2、IL-12和TNF-α的水平治疗后有所下降(P<0.05)。联合治疗组的疾病控制率为78.6%,与对照组(53.6%)的差别有统计学意义(P<0.05),KPS评分总提高率为82.14%,与对照组的57.14%差别有统计学意义(P<0.05)。结论:与单纯化疗相比,DC-CIK联合化疗能提高患者的免疫功能及生活质量,DC-CIK免疫治疗联合化疗可望成为胃癌有效的过继免疫治疗方法。
Objective：To investigate clinical effects of dendritic cells（DC） co-cultured with cytokine-induced killer cells（CIK） combined with chemotherapy on patients with advanced gastric cancer. Methods：Twenty-eight patients with advanced gastric cancer who were treated with DC-CIK combined with chemotherapy,were taken as the combined treatment group. Another twenty-eight patients who were treated with chemotherapy alone during the same period were taken as controls. T lymphocyte subtypes,intra-cellular cytokines in peripheral blood of the patients and performance status（Karnofsky,KPS） were compared between the two groups. The clinical effects were analysed. The safety were observed. Results：The ratios of CD3＋,CD4＋,CD56＋ and CD4＋/CD8＋ did not change obviously in the combined treatment group and decreased in the control group after treatment,which showed significant statistical differences （P 〈 0.05）. The IL-12 and IFN-γ were increased after treatment in the combined treatment group（P 〈 0.05）. The IL-2,IL-12 and TNF-αwere decreased in the control group after treatment（P 〈 0.05）. The disease control rate（DCR） of the combined therapy group and the control group were 78.6% and 53.6% respectively,which showed a significant difference（P 〈 0.05）. The effective rate of KPS were 82.14% and 57.14% respectively（P 〈 0.05）. Conclusion：DC-CIK cells combined with chemotherapy can improve immune functions and elevate life quality of the patients in comparision to those who take chemotherapy alone. DC-CIK cells combined with chemotherapy is likely to be an effective adoptive immunotherapy for gastric cancer.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2014年第1期36-40,共5页
Journal of Nanjing Medical University(Natural Sciences)
基金
苏州市科技发展计划项目(SZS201004)
